title: Inhibition of LPS-induced iNOS, COX-2 and inflammatory mediator expression by paeonol through the MAPKs inactivation in RAW 264.7 cells.
abstract: We evaluated the in vivo anti-inflammatory and analgesic activities of orally administered paeonol in mice, and also investigated the anti-inflammatory activity of paeonol in a cell line. Paeonol significantly reduced the edema induced by arachidonic acid in rats. The analgesic effects were assayed using 2 different models, i.e., by acetic acid-induced writhing response and by formalin induced licking and biting time. Moreover, we examined the effects of paeonol on the release of inflammatory mediators such as NO, PGE(2) and IL-6. Our results demonstrated that paeonol inhibited LPS induced expression of NO, PGE(2) and IL-6. Paeonol prevented LPS induced iNOS, COX-2 and ERK activation. Therefore, paeonol appears to have potential as a treatment for inflammatory disease and analgesic.
authors.affiliation: Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Wonkwang-Oriental Medicines Research Institute, Iksan, Chonbuk, Republic of Korea.
authors.forename: Hee-Sung
authors.initials: HS
authors.lastname: Chae
authors.forename: Ok-Hwa
authors.initials: OH
authors.lastname: Kang
authors.forename: Young-Seob
authors.initials: YS
authors.lastname: Lee
authors.forename: Jang-Gi
authors.initials: JG
authors.lastname: Choi
authors.forename: You-Chang
authors.initials: YC
authors.lastname: Oh
authors.forename: Hye-Jin
authors.initials: HJ
authors.lastname: Jang
authors.forename: Min-San
authors.initials: MS
authors.lastname: Kim
authors.forename: Jong-Hak
authors.initials: JH
authors.lastname: Kim
authors.forename: Seung-Il
authors.initials: SI
authors.lastname: Jeong
authors.forename: Dong-Yeul
authors.initials: DY
authors.lastname: Kwon
mesh_terms: D000098:Acetophenones / Q000494:pharmacology* / Q000627:therapeutic use; D000700:Analgesics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002470:Cell Survival; D051546:Cyclooxygenase 2 / Q000378:metabolism; D031105:Cynanchum; D015232:Dinoprostone / Q000378:metabolism; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010146:Pain / Q000188:drug therapy; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology*; D018517:Plant Roots; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000098:Acetophenones; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D015850:Interleukin-6; D008070:Lipopolysaccharides; D010936:Plant Extracts; D009569:Nitric Oxide; C013638:paeonol; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; D020928:Mitogen-Activated Protein Kinases; D015232:Dinoprostone